Navigation Links
New Data Demonstrated Efficacy and Safety of Initial Combination Therapy with Welchol(R) (colesevelam HCl) and Metformin in Drug-Naive Adult Type 2 Diabetes Patients
Date:6/26/2010

e diarrhea (12 percent) and nausea (12 percent); the most common non-gastrointestinal adverse events were headache (8 percent), influenza (8 percent), and dizziness (6 percent).  Mild hypoglycemia was reported in two patients treated with Welchol (colesevelam HCl) and metformin compared with three patients receiving metformin and placebo.  By the end of the study, weight decreased by 2.1 kg in each group.  

About Welchol

Approved in 2000 to lower LDL cholesterol and in 2008 as add-on therapy for glycemic control in adults with type 2 diabetes, Welchol is approved by the U.S. Food and Drug Administration (FDA) as an adjunct to diet and exercise to reduce elevated LDL-C and improve glycemic control in adults with primary hyperlipidemia and type 2 diabetes, two chronic health conditions.  Welchol should not be used for the treatment of type 1 diabetes or for the treatment of diabetic ketoacidosis.  Welchol has not been studied in type 2 diabetes as monotherapy or in combination with a dipeptidyl peptidase 4 inhibitor and has not been extensively studied in combination with thiazolidinediones.  Welchol has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias.  Welchol is available in two formulations, Welchol tablets and Welchol® for Oral Suspension.

In clinical studies of adult patients with type 2 diabetes, Welchol lowered A1C, fasting plasma glucose and LDL-C, important risk factors for cardiovascular disease.*  In clinical studies of patients with elevated LDL-C, Welchol lowered LDL-C when used as monotherapy, when added to statin therapy, or as initial combination with statin therapy.(7)

*The effect of Welchol on cardiovascular morbidity and mortality has not been determined.

IMPORTANT INFORMATION ABOUT WELCHOL (colesevelam HCl)


'/>"/>
SOURCE Daiichi Sankyo
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. New Data Show Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Demonstrated Significant ADHD Symptom Reduction when Assessed Using the Oppositional Subscale of the Conners ADHD Rating Scale
2. ULORIC(R) (febuxostat) Demonstrated Efficacy for Management of Hyperuricemia in Patients with Gout
3. Solos Endoscopy, Inc.s MammoView(TM) Product Line to be Demonstrated at the 95th Annual American College of Surgeons Clinical Congress
4. Lurasidone Demonstrated Efficacy in Treating Patients With Schizophrenia in Pivotal Phase 3 Study
5. 5-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH
6. Data Demonstrated ACTEMRA(R) (tocilizumab) Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients
7. IMPACT Study Showed Longer Valcyte(R) (valganciclovir hydrochloride tablets) Treatment Demonstrated Better Protection Against Cytomegalovirus (CMV) Disease One Year Post-Transplant
8. New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI)
9. Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients
10. Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD
11. New Study Demonstrated ACTEMRA(R) (tocilizumab) Inhibited Progression of Joint Damage in Rheumatoid Arthritis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... , May 22, 2015 Electrophysiologist Kevin ... recently traveled to Boston, MA ... the 2015 Heart Rhythm Society conference. These scientific ... focus on the ideas, people and technology that ... is a hybrid, minimally invasive cardiac operation that ...
(Date:5/22/2015)... 22, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a ... and regeneration, today announced that J.J. Finkelstein , ... a corporate overview at two upcoming investor conferences. ... 4 th Annual Microcap Conference on Thursday May ... at 11:00 am EDT.  A webcast will be ...
(Date:5/22/2015)... May 22, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... peer-reviewed publication of the results of the Company,s ... preservative-free eye drops) for the treatment of dry ... (CAE ® ) model.  The exploratory study was ... were previously disseminated by the Company in a ...
Breaking Medicine Technology:St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 3RegeneRx to Present at 2 Investor Conferences 2RegeneRx to Present at 2 Investor Conferences 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4
... 22, 2011 Terso Solutions, Inc. has expanded its ... new refrigerator that is well-suited for hospital and ... the new refrigerator makes better use of space, reduces ... products such as reagents, cardiovascular products, tissue samples, and ...
... U.S. Food and Drug Administration today announced that Terumo ... two of its officers, Mark A. Sutter, president and ... Quality Assurance and Operations, have signed a consent decree ... ) The consent decree, to be ...
Cached Medicine Technology:Terso Solutions Launches New RFID-Enabled Refrigerator for Hospital and Laboratory Inventory Management 2FDA: Michigan Heart-Lung Bypass Machine Manufacturer Enters Into Consent Decree 2FDA: Michigan Heart-Lung Bypass Machine Manufacturer Enters Into Consent Decree 3
(Date:5/25/2015)... New York, New York (PRWEB) May 25, 2015 ... ( http://www.consumerinjurylawyers.com/depuy-pinnacle/lawsuit ) continue to move forward in ... District Court, Northern District of Texas. According to ... have asked the Court to modify the Case ... Disclose Health Information. Among other things, the Motion ...
(Date:5/25/2015)... White Plains, NY (PRWEB) May 25, 2015 ... LEED AP, principal of PBDW Architects in New York City, ... which is part of the hospital’s ongoing Legacy Lobby Lecture ... campus in White Plains. White is the great grandson of ... firm responsible for the design of Burke’s campus 100 years ...
(Date:5/24/2015)... Dallas, TX (PRWEB) May 24, 2015 ... the Global and Chinese Enterokinase Industry, 2009-2019 Market Research ... as it is an exhaustive study on the present ... a special insight into the growing Chinese market of ... market and the overall status of the manufacturers in ...
(Date:5/24/2015)... ProPin is a set of self-animating ... Utilize ProPin to pin point locations on a map, to ... , ProPin allows users to choose from 30 simplistic presets with ... on-screen controls, video editors can easily manipulate ProPin presets as a ... with absolute ease. , Using ProPin is easy, simply drag a ...
(Date:5/23/2015)... City, FL (PRWEB) May 23, 2015 On ... to build a new playground for Branches Florida City exactly ... the former play space in 2010. , A large fire ... new playground on May 23, 2010 in the middle of ... watched. The fire was later declared arson even though it ...
Breaking Medicine News(10 mins):Health News:Federal DePuy Pinnacle Hip Lawsuits Move Forward, as Plaintiffs Seek to Modify Order Pertaining to Health Authorizations 2Health News:Federal DePuy Pinnacle Hip Lawsuits Move Forward, as Plaintiffs Seek to Modify Order Pertaining to Health Authorizations 3Health News:Burke Rehabilitation Hospital Welcomes Architect Samuel White, Descendant of McKim, Mead and White, for Legacy Lobby Lecture 2Health News:Burke Rehabilitation Hospital Welcomes Architect Samuel White, Descendant of McKim, Mead and White, for Legacy Lobby Lecture 3Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 2Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 3Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 4Health News:Developers at Pixel Film Studios Release ProPin for Final Cut Pro X. 2Health News:Five Years After Fire, Branches Rebuilds Playground 2
... The FDA approved Tibotec,Pharmaceutical,s novel non-nucleoside ... announced introductory pricing for,the eagerly anticipated new ... other recently introduced antiretrovirals., "The efficacy ... DUET,studies is impressive. INTELENCE is an important ...
... Protects Sensitive Customer Health Care ... Data on Laptops and ... a global,leader in enterprise data protection, today announced that Payformance,Health, ... Electronic Funds Transfer (EFT) and Electronic Remittance,Advice (ERA) services, has ...
... reveals Boomers feel young, but often ignore important, health issues; company ... ... ST. LOUIS, Jan. 31 Baby boomers are living,longer and leading ... it comes to long-term health. According to a,recent survey by Energizer Holdings, ...
... ... -- Revises 2008 EPS Guidance Primarily to Reflect the Sale of Medical ... Imaging, -- Reaffirms Expected Non-GAAP EPS CAGR of at ... Through 2010, Subject to Certain Assumptions, -- Completes Sale of Medical Imaging Business, Reports as Discontinued, ...
... PARK CITY, Utah, Jan. 31 Nutraceutical,International Corporation (Nasdaq: ... first quarter ended December 31, 2007. Net sales for ... $35.8 million for the,same quarter of fiscal 2007. For ... million, or $0.28 diluted earnings per share, compared to,net ...
... Canadian Regulatory Authorities Approve 3f(R) Aortic Bioprosthesis for Sale ... ... Company Updates Financial Outlook for 2008, MINNEAPOLIS, Jan. 31 ... products and services, today announced it has received a request,for additional information and ...
Cached Medicine News:Health News:Tibotec Pharmaceuticals a Respectful Partner to HIV Community in Pricing of Novel New HIV NNRTI, INTELENCE 2Health News:Health Care Solutions Provider Payformance Health Standardizes on PGP Encryption for Data Security 2Health News:Health Care Solutions Provider Payformance Health Standardizes on PGP Encryption for Data Security 3Health News:Health Care Solutions Provider Payformance Health Standardizes on PGP Encryption for Data Security 4Health News:Boomers: Feeling Young or Fooling Themselves? 2Health News:Boomers: Feeling Young or Fooling Themselves? 3Health News:Boomers: Feeling Young or Fooling Themselves? 4Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 2Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 3Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 4Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 5Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 6Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 7Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 8Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 9Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 10Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 11Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 12Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 13Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 14Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 15Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 16Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 17Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 18Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 19Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 20Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 21Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 22Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 23Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 24Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 25Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 26Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 27Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 28Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 29
Full Handle Laseredge Stab Blade Knife, 22.5 blade. Blade tip dimension: 10.7 mm x 1.8 mm x 4.2 mm....
18 gauge tapered fine tip. Lightweight design offers precise hemostasis. Pencil design minimizes tissue trauma and induced astigmatism. Knurled handle provides a sure grip and better manipulation....
Set consist of two 27 gauge, stainless steel probes with blunt tips. Probes are 11.5 cm (4.5 inches) long with 30.5 cm (12 inches) of flexible tubing (O.D. - 0.60 mm, I.D. - 0.30 mm) attached onto th...
Curved, soft flexible tip allows atraumatic entry through a retinal tear or hole for aspiration of subretinal fluids. 20 gauge x 25 mm cannula attached to 25 gauge x 6 mm tip with 13 mm flexible tubi...
Medicine Products: